German pharmaceutical
manufacturer Boehringer Ingelheim
told Reuters it is facing more than
2,000 lawsuits in the United States
over claims its blockbuster drug
Pradaxa, one of a new class of
stroke prevention therapies (novel
anticoagulants - NOACs), caused
severe and fatal bleeding.
“We are certain that we can
show in the legal cases that
we have worked very carefully
and responsibly in research,
development and marketing of
Pradaxa,” the company said in a
written statement.The above article was sent to subscribers in Pharmacy Daily's issue from 17 Feb 14 To see the full newsletter, see the embedded issue below or CLICK HERE to download Pharmacy Daily from 17 Feb 14
IN WESTERN Australia, Michael’s Chemist Group has started stocking therapeutic Nicotine Vaping Products (NVPs), pursuant to the Federal Government’s new vaping laws (PD 25 Mar).
FREE Pharmacy Daily subscription - never miss another story!
to top
Subscribe to Pharmacy Daily
Pharmacy Daily subscription confirmation
Thank you for signing up! Check your email inbox – you should shortly receive a message with a link which must be clicked to confirm your subscription.
Once you’ve done that you will begin receiving Pharmacy Daily as soon as the next issue is published.